Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising fungal infection treatment study halted early

NCT ID NCT05238116

Disease control Sponsor: Pulmocide Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding an inhaled medication (PC945) to standard antifungal drugs could help people with a severe, hard-to-treat lung fungal infection called invasive pulmonary aspergillosis. The trial aimed to see if the combination improved survival and response by day 84. Unfortunately, the study was stopped early, so we have limited information on its effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

85 people

The number who actually took part.

Started

Jun 2022

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant has proven or probable IPA according to the modified 2019 European Organization for Research and Treatment of Cancer/ Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) consensus definitions or according to the 2010 International Society for Heart and Lung Transplantation (ISHLT) consensus statements for the definitions of infections in cardiothoracic transplant recipients. 2. Participant's IPA has failed to respond to adequate antifungal therapy. Exclusion Criteria: 1. Participant with a known or suspected concomitant medical condition or post-surgery complication that, in the opinion of the Investigator, may jeopardize adherence to the protocol requirements or impede the accurate measurement of efficacy or may be an unacceptable additional risk to the Participant should he/she participate in the study. 2. Participant who has previously received PC945. 3. Participant with a known history of allergy, hypersensitivity, or any previous serious reaction to any component of the PC945 or placebo formulations. 4. Participant who has recently received, is receiving or due to receive at any time during the study, an investigational medicinal agent that does not have any regulatory approved indications. Subjects who are participating in any other trials e.g., Observational, diagnostic or using medications with an approved indication may be allowed to participate after consultation with the sponsor on an individual basis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Refractory ipa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

invasive aspergillosis Invasive Pulmonary Aspergillosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Refractory ipa

Contacts and locations

Locations

  • Clinical R Site

    Los Angeles, California, 90095, United States

  • Clinical Research Site

    La Jolla, California, 92037, United States

  • Clinical Research Site

    Los Angeles, California, 90048, United States

  • Clinical Research Site

    Sacramento, California, 95817, United States

  • Clinical Research Site

    Jacksonville, Florida, 32224, United States

  • Clinical Research Site

    Baltimore, Maryland, 21287, United States

  • Clinical Research Site

    Ann Arbor, Michigan, 48109, United States

  • Clinical Research Site

    Minneapolis, Minnesota, 55455, United States

  • Clinical Research Site

    St Louis, Missouri, 63110, United States

  • Clinical Research Site

    The Bronx, New York, 10467, United States

  • Clinical Research Site

    Philadelphia, Pennsylvania, 19014, United States

  • Clinical Research Site

    Pittsburgh, Pennsylvania, 15213, United States

  • Clinical Research Site

    Madison, Wisconsin, 53792, United States

  • Clinical Research Site

    Caba, Buenos Aires, C1199ABB, Argentina

  • Clinical Research Site

    La Plata, Buenos Aires, B1900, Argentina

  • Clinical Research Site

    Caba, Buenos Aries, C1118AAT, Argentina

  • Clinical Research Site

    Rosario, Santa Fe Province, S2000CVB, Argentina

  • Clinical Research Site

    Mendoza, M5500, Argentina

  • Clinical Research Site

    Melbourne, Victoria, 3004, Australia

  • Clinical Research Site

    Parkville, Victoria, 3050, Australia

  • Clinical Research Site

    Graz, Styria, 8036, Austria

  • Clinical Research Site

    Vienna, 1090, Austria

  • Clinical Research Site

    Brussels, B-1070, Belgium

  • Clinical Research Site

    Brussels, B-1200, Belgium

  • Clinical Research Site

    Leuven, B-3000, Belgium

  • Clinical Research Site

    Curitiba, Paraná, 80060-900, Brazil

  • Clinical Research Site

    Curitiba, Paraná, 81520060, Brazil

  • Clinical Research Site

    Passo Fundo, Rio Grande do Sul, 99010260, Brazil

  • Clinical Research Site

    Porto Alegre, Rio Grande do Sul, 90035903, Brazil

  • Clinical Research Site

    Santa Maria, Rio Grande do Sul, 97105900, Brazil

  • Clinical Research Site

    Jaú, São Paulo, 17210-080, Brazil

  • Clinical Research Site

    Santos, São Paulo, 11075101, Brazil

  • Clinical Research Site

    Hamilton, Ontario, L8V 1C3, Canada

  • Clinical Research Site

    Toronto, Ontario, M5G 2C4, Canada

  • Clinical Research Site

    Toronto, Ontario, M6G2N2, Canada

  • Clinical Research Site

    Valparaíso, 2570017, Chile

  • Clinical Research Site

    Montería, Departamento de Córdoba, 230002, Colombia

  • Clinical Research Site

    Cali, Valle del Cauca Department, 760032, Colombia

  • Clinical Research Site

    Paris, 75015, France

  • Clinical Research Site

    Strasbourg, 67091, France

  • Clinical Research Site

    Würzburg, Bavaria, 97080, Germany

  • Clinical Research Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Clinical Research Site

    Athens, 11527, Greece

  • Clinical Research Site

    Thessaloniki, 57010, Greece

  • Clinical Research Site

    Bengaluru, Karnataka, 560034, India

  • Clinical Research Site

    Hyderabad, Telangana, 500082, India

  • Clinical Research Site

    New Delhi, 110017, India

  • Clinical Research Site

    Haifa, 3109601, Israel

  • Clinical Research Site

    Ramat Gan, 5266202, Israel

  • Clinical Research Site

    Brescia, Lombardy, 25123, Italy

  • Clinical Research Site

    Monza, 20900, Italy

  • Clinical Research Site

    Naples, 80131, Italy

  • Clinical Research Site

    Rome, 00168, Italy

  • Clinical Research Site

    Siena, 53100, Italy

  • Clinical Research Site

    Daejeon, 35015, South Korea

  • Clinical Research Site

    Incheon, 21565, South Korea

  • Clinical Research Site

    Seoul, 02841, South Korea

  • Clinical Research Site

    Seoul, 06273, South Korea

  • Clinical Research Site

    Seoul, 06351, South Korea

  • Clinical Research Site

    Seoul, 06591, South Korea

  • Clinical Research Site

    Córdoba, Andalusia, 14004, Spain

  • Clinical Research Site

    Barcelona, Catalonia, 08035, Spain

  • Clinical Research Site

    Barcelona, Catalonia, 08036, Spain

  • Clinical Research Site

    Majadahonda, Madrid, 28222, Spain

  • Clinical Research Site

    Granada, 18014, Spain

  • Clinical Research Site

    Valencia, 46026, Spain

  • Clinical Research Site

    Tapei City, Tapai, 100225, Taiwan

  • Clinical Research Site

    Kaohsiung City, 807377, Taiwan

  • Clinical Research Site

    New Taipei City, 220, Taiwan

  • Clinical Research Site

    New Taipei City, 23561, Taiwan

  • Clinical Research Site

    Khlong Luang, Changwat Pathum Thani, 12120, Thailand

  • Clinical Research Site

    Bangkok, 10400, Thailand

  • Clinical Research Site

    Bangkok, 10700, Thailand

  • Clinical Research Site

    Khon Kaen, 40002, Thailand

  • Clinical Research Site

    Harefield, Middlesex, UB9 6JH, United Kingdom

  • Clinical Research Site

    London, SE5 9RS, United Kingdom

  • Clinical Research Site

    London, SW17 0QT, United Kingdom

  • Clinical Research Site

    London, W12 0HS, United Kingdom

  • Clinical Research Site

    Manchester, M23 9LT, United Kingdom

  • Clinical Research Site 1

    Houston, Texas, 77030, United States

  • Clinical Research Site 1

    Pune, Maharashtra, 411004, India

  • Clinical Research Site 2

    Houston, Texas, 77030, United States

  • Clinical Research Site 2

    Pune, Maharashtra, 411004, India